Benzinga · Aug 21, 2026
One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story
Werewolf Therapeutics surged after announcing a $500 million merger with Ambros Therapeutics, putting focus on Israel Englander's holding.
HO
NASDAQ · HOWL
Werewolf Therapeutics, Inc.
Healthcare · Biotechnology
$0.96
Up+$0.02 (+1.75%)
Updated Sep 2, 2026, 6:49 AM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 53.38M
- P/E ratio
- -0.69
- Dividend yield
- 0.00%
- 52-week range
- $0.27 – $2.38
- Volume
- 982.57K
- Avg. volume
- 938.4K
Price performance
HOWL price history
1M range · 21 trading sessions · Daily adjusted prices
HOWL closed at $0.96 after 21 trading sessions, up 130.95% for the selected period.
- Last close
- $0.96
- Period change
- +130.95%
- Period low
- $0.38
- Period high
- $0.99
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 1, 2026 | $0.9174 | $0.9675 | $0.912 | $0.9575 | 982.57K |
| Aug 31, 2026 | $0.935 | $0.9489 | $0.90 | $0.941 | 1.27M |
| Aug 28, 2026 | $0.9747 | $1.03 | $0.9273 | $0.9433 | 2.33M |
| Aug 27, 2026 | $0.99 | $0.9981 | $0.9144 | $0.9708 | 2.22M |
| Aug 26, 2026 | $0.90 | $1.05 | $0.8979 | $0.9888 | 11.62M |
| Aug 25, 2026 | $0.8656 | $0.9344 | $0.84 | $0.89 | 6.43M |
| Aug 24, 2026 | $0.85 | $0.90 | $0.811 | $0.8833 | 12.04M |
| Aug 21, 2026 | $0.98 | $1.05 | $0.86 | $0.8735 | 296.73M |
| Aug 20, 2026 | $0.4221 | $0.44 | $0.4033 | $0.4312 | 66.02M |
| Aug 19, 2026 | $0.4092 | $0.42 | $0.4033 | $0.4093 | 155.58K |
| Aug 18, 2026 | $0.3997 | $0.4161 | $0.3997 | $0.4092 | 87.22K |
| Aug 17, 2026 | $0.411 | $0.425 | $0.3922 | $0.4055 | 292.16K |
| Aug 14, 2026 | $0.40 | $0.425 | $0.3866 | $0.4047 | 274.54K |
| Aug 13, 2026 | $0.39 | $0.4022 | $0.3821 | $0.386 | 114.59K |
| Aug 12, 2026 | $0.395 | $0.40 | $0.363 | $0.3819 | 452.21K |
| Aug 11, 2026 | $0.40 | $0.40 | $0.37 | $0.3837 | 146.14K |
| Aug 10, 2026 | $0.3967 | $0.4126 | $0.382 | $0.382 | 157.71K |
| Aug 7, 2026 | $0.4067 | $0.426 | $0.3971 | $0.3971 | 391.14K |
| Aug 6, 2026 | $0.411 | $0.411 | $0.3973 | $0.4028 | 97.32K |
| Aug 5, 2026 | $0.4096 | $0.4193 | $0.3916 | $0.402 | 274.63K |
| Aug 4, 2026 | $0.3708 | $0.4197 | $0.3702 | $0.4146 | 605.04K |
Latest HOWL news
The latest Smart Investors Daily articles mentioning HOWL.
Stock researchCompany · Overview
HOWL research
Overview
Company profile and research snapshot.
Company profile
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $12.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 19, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 18, 2025 | B of A Securities | Buy | — |
| Aug 25, 2025 | B of A Securities | Buy | — |
| Aug 21, 2025 | JMP Securities | Market Outperform | — |
| May 9, 2025 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 21, 2026
Werewolf Therapeutics (HOWL) Stock Is Trending Overnight—Here's Why It Jumped 90% After Hours
Werewolf Therapeutics shares surge 89.94% after hours as $33 million deal with EMD Serono brings fresh non-dilutive cash.
Benzinga · Jul 31, 2026
Werewolf Therapeutics Q2 EPS $0.08 Beats $(0.29) Estimate, Sales $21.000M
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.29) by 127.59 percent. This is a 120 percent increase over losses of $(0.40) per share
Benzinga · Feb 24, 2026
Werewolf Therapeutics shares are trading higher after the company announced plans to explore strategic alternatives.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
